ClinicalTrials.gg
Active, not recruitingNCT06395948Updated Nov 3, 2026

A Study Evaluating APG777 in Atopic Dermatitis

A Phase 2 interventional study of APG777 and Placebo in Atopic Dermatitis, sponsored by Apogee Therapeutics, Inc.. Active, not recruiting at 94 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Apogee Therapeutics, Inc. (part of AbbVie) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
470
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies in Dermatitis, Atopic by AbbVie — 3 open to participants now, 12 under way, 4 of them phase 3. Dermatitis, Atopic · AbbVie.

Enrollment
8th of 22
470 · median 228
Started
2024
with 8 others
Phase 2
6 of 34
2 open now
Primary completion
2026-11
later than 2 of 11 live
Registered
25th of 34
by date

Among the 34 studies in Dermatitis, Atopic by AbbVie, this one is the 8th largest by enrollment of the 22 interventional ones that give a count, is one of 9 that started in 2024, is one of 6 in phase 2, reaches primary completion later than 2 of the 11 other live ones, and was the 25th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

3 of the 34 studies in Dermatitis, Atopic by AbbVie are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Dermatitis, Atopic by AbbVie, or all of them as a file.
02

Study summary

This is a two-part study that will evaluate the safety and efficacy of APG777 in participants with moderate-to-severe Atopic Dermatitis (AD). Part A (Proof-of-concept) and Part B (Dose-regimen Finding) will evaluate the safety and efficacy of various induction and maintenance dose regimens of APG777 compared to placebo. The study duration for any individual participant will be up to 106 weeks which includes: screening, induction, maintenance, and post-treatment follow-up periods. Participants randomized in Part A are not permitted to participate in Part B.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

Keywords

  • Atopic Dermatitis
  • APG777
  • Safety
  • Efficacy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a diagnosis of AD that has been present for >=1 year prior to the Screening visit
  • Moderate-to-severe AD at Screening and Baseline visits
  • History of inadequate response to treatment with topical medications, or medical determination that topical therapies are inadvisable
  • Applied a stable dose of non-medicated over-the-counter emollient/moisturizer of their choice on their skin for >=14 days prior to Baseline visit and agrees to continue using the same moisturizer throughout the study except the day of the study visits.
  • Have completed itch questionnaires in the electronic diary for >=4 of 7 days prior to Baseline visit

Exclusion criteria

Exclusion Criteria:

  • Participation in a prior study with APG777.
  • Prior treatment with protocol-specified monoclonal antibodies (mAbs)
  • Has used any AD-related topical medications within 7 days prior to Baseline visit.
  • Has used systemic treatments (other than biologics) and/or phototherapies and/or laser therapy that could affect AD within 4 weeks prior to Baseline visit

Note: Other protocol defined inclusion/exclusion criteria may apply.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
470 participants (actual)

Study arms

  • Experimental
    Part A: Induction Period: APG777

    Participants will receive APG777 per protocol defined dosing regimen

    Drug: APG777

  • Placebo comparator
    Part A: Induction Period: Placebo

    Participants will receive matching Placebo injections per protocol defined dosing regimen

    Drug: Placebo

  • Experimental
    Part A: Maintenance Period: APG777

    Participants will receive 1 of 2 maintenance regimens of APG777 per protocol defined dosing regimen

    Drug: APG777

  • Experimental
    Part B: Induction Period: APG777

    Participants will receive APG777 in 1 of 3 regimens per protocol defined dosing regimen

    Drug: APG777

  • Placebo comparator
    Part B: Induction Period: Placebo

    Participants will receive matching placebo injections per protocol defined dosing regimen

    Drug: Placebo

  • Experimental
    Part B: Maintenance Period: APG777

    Participants will receive APG777 per protocol defined dosing regimen

    Drug: APG777

Interventions

  • DrugAPG777

    APG777 subcutaneous injection

  • DrugPlacebo

    Matching placebo subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Part A: Percent Change From Baseline in Eczema Area and Severity Index (EASI)

    Time frame: Baseline and at Week 16

  2. Part B: Proportion of participants who achieve EASI 75 at Week 16

    Time frame: At Week 16

Secondary outcomes

  1. Part A and B: Number of Participants with Treatment Emergent Adverse Events (TEAEs)

    Time frame: Up to 106 Weeks

  2. Part A and B: Change from Baseline in EASI

    Time frame: Baseline, through Week 16 and at Week 52

  3. Part A and B: Percent Change from Baseline in EASI

    Time frame: Baseline through Week 16 and at Week 52

  4. Part A and B: Proportion of Participants Achieving EASI 50, 75, 90, and 100 Score

    Time frame: Baseline through Week 16 and at Week 52

  5. Part A and B: Proportion of Participants Achieving a Validated Investigator Global Assessment (vIGA-AD) Score of 0 (clear) or 1 (almost clear) and a >= 2-Point Reduction

    Time frame: Baseline through Week 16 and at Week 52

  6. Part A and B: Change from Baseline in Body Surface Area (BSA) Involvement

    Time frame: Baseline through Week 16 and at Week 52

  7. Part A and B: Proportion of Participants Achieving a >= 4 Point Improvement in the Weekly Mean of the Daily Itch Numeric Rating Scale (I-NRS)

    Time frame: Baseline through Week 16 and at Week 52

  8. Part A and B: Percent Change from Baseline in the Weekly Mean of the Daily I-NRS

    Time frame: Baseline through Week 16 and at Week 52

  9. Part A and B: Serum Concentrations of APG777 Over Time

    Time frame: Up to 106 Weeks

  10. Part A and B: Predose Serum Concentrations of APG777 (Ctrough)

    Time frame: Up to 106 Weeks

  11. Part A and B: Maximum concentration (Cmax) of APG777

    Time frame: Up to 106 Weeks

  12. Part A and B: Time to reach Cmax (tmax)

    Time frame: Up to 106 Weeks

  13. Part A and B: Area Under the Concentration-Time Curve (AUC) from Time 0 to Time t (AUC0-t) in the Induction Period

    Time frame: Baseline to 16 Weeks

  14. Part A and B: AUC Over the Dosing Interval (AUC0-tau) in the Maintenance Period

    Time frame: 16 Weeks to 52 Weeks

07

Study locations

94 sites
  • Investigational Site
    Fountain Valley, California 92708, United States
  • Investigational Site
    Los Angeles, California 90024, United States
  • Investigational Site
    San Diego, California 92123, United States
  • Investigational Site
    New Haven, Connecticut 06519, United States
  • Investigational Site
    Coral Gables, Florida 33134, United States
  • Investigational Site
    Jacksonville, Florida 32256, United States
  • Investigational Site
    Margate, Florida 33063, United States
  • Investigational Site
    Douglasville, Georgia 30135, United States
  • Investigational Site
    Chicago, Illinois 60657, United States
  • Investigational Site
    Skokie, Illinois 60077, United States
  • Investigational Site
    West Lafayette, Indiana 47906, United States
  • Investigational Site
    Bowling Green, Kentucky 42104, United States
  • Investigational Site
    Rockville, Maryland 20850, United States
  • Investigational Site
    Detroit, Michigan 48202, United States
  • Investigational Site
    Troy, Michigan 48084, United States
  • Investigational Site
    Portsmouth, New Hampshire 13801, United States
  • Investigational Site
    New York, New York 10023, United States
  • Investigational Site
    Wilmington, North Carolina 28403, United States
  • Investigational Site
    Boardman, Ohio 44512, United States
  • Investigational Site
    Mason, Ohio 45040, United States
  • Investigational Site
    Portland, Oregon 97201, United States
  • Investigational Site
    Pittsburgh, Pennsylvania 15213, United States
  • Investigational Site
    Charleston, South Carolina 29425, United States
  • Investigational Site
    Nashville, Tennessee 37215, United States
  • Investigational Site
    Dallas, Texas 75230, United States
  • Investigational Site
    Dallas, Texas 75235, United States
  • Investigational Site
    San Antonio, Texas 78213, United States
  • Investigational Site
    Norfolk, Virginia 23502, United States
  • Investigational Site
    Mill Creek, Washington 98012, United States
  • Investigational Site
    Calgary, Alberta T2J 7E1, Canada
  • Investigational Site
    Calgary, Alberta T3E 0B2, Canada
  • Investigational Site
    Edmonton, Alberta T5J 3S9, Canada
  • Investigational Site
    Vancouver, British Columbia V5Z 4E8, Canada
  • Investigational Site
    Winnipeg, Manitoba R3M 3Z4, Canada
  • Investigational Site
    Fredericton, New Brunswick E3B 1G9, Canada
  • Investigational Site
    Ajax, Ontario L1S 7K8, Canada
  • Investigational Site
    Markham, Ontario L3P 1X3, Canada
  • Investigational Site
    Mississauga, Ontario L4Y 4C5, Canada
  • Investigational Site
    Ottawa, Ontario K1K 4L2, Canada
  • Investigational Site
    Peterborough, Ontario K9J 5K2, Canada
  • Investigational Site
    Toronto, Ontario M3B 0A7, Canada
  • Investigational Site
    Toronto, Ontario M4E 2Y9, Canada
  • Investigational Site
    Toronto, Ontario M4W 2N4, Canada
  • Investigational Site
    Montreal, Quebec H2X 2V1, Canada
  • Investigational Site
    Québec, Quebec G1V4X7, Canada
  • Investigational Site
    Prague, 10000, Czechia
  • Investigational Site
    Prague, 10034, Czechia
  • Investigational Site
    Prague, 11000, Czechia
  • Investigational Site
    Prague, 15006, Czechia
  • Investigational Site
    Prague, 16000, Czechia
  • Investigational Site
    Rouen, Normandy 76031, France
  • Investigational Site
    Martigues, 13500, France
  • Investigational Site
    Nantes, 44093, France
  • Investigational Site
    Freiburg im Breisgau, Baden-Wurttemberg 79104, Germany
  • Investigational Site
    Heidelberg, Baden-Wurttemberg 69120, Germany
  • Investigational Site
    Tübingen, Baden-Wurttemberg 72076, Germany
  • Investigational Site
    Augsburg, Bavaria 86179, Germany
  • Investigational Site
    München, Bavaria 81377, Germany
  • Investigational Site
    Blankenfelde-Mahlow, Brandenburg 15831, Germany
  • Investigational Site
    Darmstadt, Hesse 64283, Germany
  • Investigational Site
    Frankfurt am Main, Hesse 60590, Germany
  • Investigational Site
    Bad Bentheim, Lower Saxony 48455, Germany
  • Investigational Site
    Münster, North Rhine Westfalia 48149, Germany
  • Investigational Site
    Dresden, Saxony 01307, Germany
  • Investigational Site
    Kiel, Schleswig-Holstein 24105, Germany
  • Investigational Site
    Lübeck, Schleswig-Holstein 23538, Germany
  • Investigational Site
    Berlin, 10117, Germany
  • Investigational Site
    Hamburg, 20246, Germany
  • Investigational Site
    Hamburg, 20354, Germany
  • Investigational Site
    Debrecen, Hajdú-Bihar 4032, Hungary
  • Investigational Site
    Budapest, 1085, Hungary
  • Investigational Site
    Szeged, 6720, Hungary
  • Investigational Site
    Wroclaw, Lower Silesian Voivodeship 50-450, Poland
  • Investigational Site
    Wroclaw, Lower Silesian Voivodeship 51-503, Poland
  • Investigational Site
    Lublin, Lublin Voivodeship 20-573, Poland
  • Investigational Site
    Warsaw, Masovian Voivodeship 01-595, Poland
  • Investigational Site
    Warsaw, Masovian Voivodeship 02-482, Poland
  • Investigational Site
    Gdansk, Pomeranian Voivodeship 80-546, Poland
  • Investigational Site
    Katowice, Silesian Voivodeship 40-600, Poland
  • Investigational Site
    Sosnowiec, Silesian Voivodeship 41-218, Poland
  • Investigational Site
    Szczecin, West Pomeranian Voivodeship 71-500, Poland
  • Investigational Site
    Krakow, Woj. Małopolskie 30-727, Poland
  • Investigational Site
    Lodz, Łódź Voivodeship 90-338, Poland
  • Investigational Site
    Santiago de Compostela, A Coruña 15706, Spain
  • Investigational Site
    Badalona, Barcelona 08916, Spain
  • Investigational Site
    Las Palmas de Gran Canaria, Canary Islands 35010, Spain
  • Investigational Site
    Alicante, 03010, Spain
  • Investigational Site
    Barcelona, 08041, Spain
  • Investigational Site
    Madrid, 28006, Spain
  • Investigational Site
    Madrid, 28040, Spain
  • Investigational Site
    Zaragoza, 50009, Spain
  • Investigational Site
    Salford, Greater Manchester M6 8HD, United Kingdom
  • Investigational Site
    Dudley, West Midlands DY1 2HQ, United Kingdom
  • Investigational Site
    London, SE1 9RT, United Kingdom
08

References and documents

Publications

  • Lim XQ, Winter E, Nograles K, Xu J, Zhang ZQ, Thankamony S, Dillinger L, Dambkowski CL. A First-in-Human, Single- and Multiple-Dose Study of APG777, a Half-Life-Extended Anti-IL-13 Monoclonal Antibody, in Healthy Volunteers. Clin Transl Sci. 2025 Dec;18(12):e70456. doi: 10.1111/cts.70456. PubMed 41422501 ↗
  • Rubio D, Zhu E, Thurston A, Funk KA, York KA, Dambkowski CL, Badger D. Preclinical Safety of APG777, A Novel Extended Half-Life Anti-Interleukin-13 Monoclonal Antibody, in Cynomolgus Monkeys. Int J Toxicol. 2025 Nov-Dec;44(6):443-450. doi: 10.1177/10915818251355584. Epub 2025 Jul 30. PubMed 40739793 ↗

Individual participant data

Plan to share: No

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Nov 2026, 31 months after the start.

Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's planned 31 months is above that.

Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2024
First posted
May 2, 2024
StartActual
Apr 29, 2024
Primary completionEst.
Nov 2026
CompletionEst.
Jun 2028
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date, contact details and site details
3 updates, last Nov 3, 2026
Show all 3 updates
  1. Nov 3, 2026
    Minor edits only
    + 2 other changes: verification date and site details
  2. Oct 13, 2026
    Minor edits only
    + 1 other change: contact details
  3. Oct 6, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06395948
Responsible party
Sponsor
First posted
May 2, 2024
Start date
Apr 29, 2024
Primary completion
Nov 2026 (estimated)
Completion
Jun 2028 (estimated)
Last update
Nov 3, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zumilokibart

Start the discussion